Dr. Benet, Professor and former Chairman (1978-1998), Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California, San Francisco, received his A.B. (English), B.S. (Pharmacy), M.S. from the University of Michigan and Ph.D. from the University of California. He has received eight honorary doctorates. His research interests, more than 530 publications, 6 books and 11 patents are in the areas of pharmacokinetics, biopharmaceutics, drug delivery and pharmacodynamics. Dr. Benet is listed by Thompson Reuters as one of the most highly cited pharmacologists worldwide, with his published peer-reviewed papers cited more than 20,000 times. His most recent work has addressed the interplay of metabolic enzymes and transport proteins as related to oral bioavailability and hepatic elimination, and the development of the Biopharmaceutics Drug Disposition Classification System (BDDCS). During 1986, Dr. Benet was a Founder and the first President of the AAPS.
More information can be found at the following link: http://profiles.ucsf.edu/leslie.benet#narrative
Rao V. Mantri is Director of Materials Science & Engineering at Bristol-Myers Squibb Company. He received his M.S. in Chemical Engineering and Ph.D. in Pharmaceutical Chemistry with honors from The University of Kansas. Since joining BMS R&D in 2000, he has held positions of increasing responsibility in design, development and technology transfer of small molecules as well as biologics drug products. In his current role, he is responsible for design, characterization & development of materials (APIs and API composites) to enable robust drug products.
More information can be found at the following link: https://www.acs.org/content/acs/en/acs-webinars/presenters/mantri-rao.html
Dr. Lawrence X. Yu is the Deputy Director for Science and Director of Chemistry at the Office of Generic Drugs, Food and Drug Administration, overseeing CMC review operation, policy development, and regulatory research with over 140 staff scientists. Dr. Yu received his B. S. in ChemE and M. S. in ChemE from Zhejiang University, his M. S. in Pharmaceutics from the University of Cincinnati, and his Ph.D. in Pharmaceutics from the University of Michigan. Prior to joining the FDA, Dr. Yu had worked at Pfizer (Upjohn) and GlaxoWellcome for 8 years. Dr. Yu’s research interests have centered on the prediction of oral drug delivery/development of pharmaceutical QbD. His compartmental absorption and transit (CAT) model has laid the foundation for GastroPLUS™ and Simcyp® software, which are widely used in industry. Dr. Yu is a fellow and past AAPS section chair and Associate Editor of the AAPS Journal. Dr. Yu has authored/co-authored over 200 papers, book chapters, and abstracts.
More information can be found at the following link: http://ispe.org/index.php/ci_id/2888/la_id/1/s_id/278819.html
Gus R. Rosania, PhD is Professor of Pharmaceutical Sciences at the University of Michigan where he has been Principal Investigator of an NIH funded, internationally-recognized research group for the past fifteen years. At the forefront of pharmacokinetics research, his lab has performed pioneering research on the transport mechanisms governing the distribution of poorly soluble small molecule drugs, from cells to whole organisms. He has published over sixty original research articles and is inventor on six patents. He is a member of the editorial board of various pharmaceutical sciences journals and has received numerous awards for his scientific contributions at the interface of chemistry, biology and pharmaceutics.
Dr. Dalton is the Dean of the College of Pharmacy at the University of Michigan.
Dr. Greg Amidon is a profesor in the Pharmaceutical Sciences Deparment of the College of Pharmacy and the previous AAPS president.
The end goals of each major part of the pharmaceutical world varies. Each has to set a tone, driven by each one's unique motivations. Regulation drives for the safety of the users. Industry drives for market approval for their drug products. Academia drives for innovation through development of basic science. At the center of the three different worlds is you, the scientist. Without you, this interplay would never exist.
We must gain a significant amount of knowledge, to encompass the single patch underlying the meeting points of each of these three potential career pathways. As our knowledge grows, we can influence how these interactions occur, thus driving scientific innovation. By coming to PGSRM, and interacting with others, you have inherently succeeded in the primary goal of relationship building. Using this, you will be able to achieve your true potential, and increase the potentials of others.
